Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
19 Julho 2023 - 5:04PM
Business Wire
Company to host conference call and webcast on
Wednesday, August 2, 2023, at 4:30 p.m. Eastern Time
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will report second quarter financial results on Wednesday,
August 2, 2023, after the close of the U.S. financial markets.
Acadia’s management team will also host a conference call and
webcast on August 2, 2023, at 4:30 p.m. Eastern Time to discuss
financial results and operations.
The conference call will be available on Acadia’s website,
www.acadia.com under the investors section and will be archived
there until September 1, 2023. The conference call may also be
accessed by registering for the call here. Once registered,
participants will receive an email with the dial-in number and
unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only approved
therapies for hallucinations and delusions associated with
Parkinson’s disease psychosis and for the treatment of Rett
syndrome. Our clinical-stage development efforts are focused on
treating the negative symptoms of schizophrenia, Prader-Willi
syndrome, Alzheimer’s disease psychosis and neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at www.acadia.com and follow us on LinkedIn and
Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to Acadia’s annual report
on Form 10-K for the year ended December 31, 2022, as well as
Acadia’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230719847037/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Jessica Tieszen
(858) 261-2950 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024